• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 17, 2019

View Archived Issues

Not everyone on board as Purdue agrees to file bankruptcy in opioid settlement

Purdue Pharma LP filed for Chapter 11 bankruptcy Monday in a first step toward reorganizing as a new company designed to benefit plaintiffs in multidistrict litigation (MDL) and the American public in general. Read More

To stay competitive, NIH's Bethesda campus needs a significant upgrade

A study two years in the making concluded that the NIH's Bethesda, Md., campus needs a $1.3 billion upgrade to its buildings and facilities in order to succeed in what it calls "a highly competitive global biomedical research environment." Read More

Cassava Sciences advances Alzheimer's candidate with phase IIb start

Following data from a small phase IIa study showing its experimental Alzheimer's disease (AD) therapy, PTI-125, led to decreases in key biomarkers of neuroinflammation and neurodegeneration, Cassava Sciences Inc. (formerly Pain Therapeutics) has dosed the first two patients in a phase IIb study of the candidate.  Read More

Lupin's MEK inhibitor draws Boehringer to potential $700M partnership for combo testing

BEIJING – After a deal with Abbvie Inc. last year, Mumbai, India-based Lupin Ltd. inked another one, this time with German pharma Boehringer Ingelheim GmbH, to deepen its drug research efforts in gastrointestinal and lung cancers. Under the new agreement, the companies will explore the potential of a combination therapy using Lupin's MEK inhibitor compound, LNP-3794, and Boehringer Ingelheim's KRAS inhibitor. Read More

Kahr aiming for I-O combo, testing DSP-107 plus Roche PD-L1 in lung cancer study

HONG KONG – In one of the latest combination efforts against cancer, Kahr Medical Ltd. is teaming up with Switzerland's Basel-based Roche Holding AG to study the use of the former's lead program, DSP-107, in combination with the latter's PD-L1-blocking checkpoint inhibitor, Tecentriq (atezolizumab), in patients with advanced non-small-cell lung carcinoma refractory to checkpoint inhibitors. Read More

Other news to note

Tarsius Pharma Ltd., of Tel-Aviv, Israel, was awarded a $2.6 million Horizon 2020 grant from the European Commission to begin clinical development of TRS, Tarsius' platform for treating autoimmune and inflammatory ocular diseases. Read More

Financings

Edigene Inc., of Beijing, said it completed an $11 million series pre-B2 financing round with series A lead investor IDG Capital and series pre-B lead investor Lilly Asia Ventures participating.  Read More

Regulatory front

When it comes to patent term extensions, a requested continued examination doesn't end until the U.S. Patent and Trademark Office (PTO) mails the notice of allowance, the U.S. Court of Appeals for the Federal Circuit said in a precedential ruling handed down Monday in Mayo Foundation for Medical Education and Research v. Iancu.  Read More

Clinical data for Sept. 16, 2019

Read More

Regulatory actions for Sept. 16, 2019

Read More

Lundbeck acquiring Alder and its CGRP migraine drug in deal valued at $1.95B

DUBLIN – H. Lundbeck A/S is entering the crowded marketplace for antibody-based migraine therapies by acquiring Alder Biopharmaceuticals Inc. for up to $1.95 billion net of cash. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe